Advertisement

Topics

Xbrane And STADA Enter Into Co-development Agreement For Xlucane

11:22 EDT 12 Jul 2018 | FinanzNachrichten

BAD VILBEL (dpa-AFX) - Xbrane Biopharma AB and STADA Arzneimittel AG have entered into a co-development agreement for Xlucane, a Lucentis (ranibizumab) biosimilar.The collaboration between Xbrane ...

Original Article: Xbrane And STADA Enter Into Co-development Agreement For Xlucane

NEXT ARTICLE

More From BioPortfolio on "Xbrane And STADA Enter Into Co-development Agreement For Xlucane"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...